Endomagnetics Appoints Strategic Distributor

Norderstedt (ots) - Endomagnetics, the company developing a
portfolio of products to improve the standard of breast cancer
management, has announced it has signed a distribution agreement with
Sysmex Europe GmbH, a subsidiary of global healthcare company Sysmex
Corporation. Sysmex has the exclusive right to provide sales and
support for Endomagnetics' SentiMag® system across the EMEA region.
This is Endomagnetics' first multi-region agreement, and it promises
to extend widely the clinical use of the company's technology.

The SentiMag® system is used as part of the current standard
sentinel lymph node (SLNB) technique, used by surgeons to monitor the
spread of cancer and to plan interventions. Unlike the present
system, Endomagnetics' technology can be used by surgeons as part of
an efficient workflow, and does not require specialist technicians to
store and manage radioisotopes. Patients are spared the anxiety of
radioactivity and the possible need to attend multiple clinics. The
system consists of the highly sensitive SentiMag® instrument and its
associated tracer, Sienna+®. The system is currently in use in 8
countries across the EU: UK, Germany, Poland, France, Italy, Belgium,
Holland, and Switzerland.

Dr Marc Thill, Head of the Department of Gynaecology and
Obstetrics and the Breast Cancer Centre at Agaplesion Markus
Hospital, Frankfurt reported: "After working with the SentiMag®
technique in my daily routine for the past few months, I have
concluded that this technique is an easy-to-use approach for
performing SLNB without radioisotopes or any time-consuming
pre-operative preparation of the patient. For that reason it may
ultimately replace the standard of care."

Endomagnetics cited Sysmex's strong history of customer support,
compatible product pipeline and focus on healthcare innovation in
developing this strategic relationship. Sysmex is the global market
leader in haematology, and has built on its successes in diagnostics
to innovate in the life science field. In particular, Sysmex has
developed a molecular diagnostics assay called OSNA (One Step Nucleic
Acid Amplification). This assay enables complete lymph nodes to be
analysed quickly, and is used routinely for analysing sentinel lymph
nodes for breast cancer in about 200 hospitals across Europe.

"SentiMag® offers hospitals and clinics a powerful, efficient new
way of locating lymph nodes to verify the spread of breast cancer,"
said Dr Michael Schaefer, Managing Director of Sysmex Europe. "It is
an excellent strategic fit with our product portfolio and an ideal
complement to our OSNA system. Our sales teams across the EU have
received very positive feedback from customers"

CEO of Endomagnetics Dr Eric Mayes commented: "We are extremely
pleased with initial customer feedback, and partnering with a group
as strong as Sysmex gives us the geographic scope and customer
support we need to really make an impact. We have been extremely
impressed with the enthusiasm of the Sysmex team in supporting our
joint product launch."

Notes to Editors:

High quality product pictures are also available.

About Endomagnetics

Endomagnetics was founded to solve cancer staging and healthcare
challenges through the application of advanced magnetic sensing
technology and nanotechnology. Endomagnetics is developing a
portfolio of medical device products based on a patented ability to
detect magnetic materials in the human body with exceptional
sensitivity. The technology was originally developed at University
College London and the University of Houston.

The company's first product, the SentiMag®, is an ultrasensitive
hand-held probe for tracking injected Sienna+® nanoscale magnetic
materials in the human body. Cambridge, UK-based Endomagnetics is in
the process of delivering its technology to global markets. For more
information please visit www.endomagnetics.com.

About Sysmex

Sysmex is a global group, with more than 40 overseas subsidiaries
conducting business in more than 170 countries. It develops, produces
and sells instruments, reagents and software used in in-vitro
diagnostics in hospitals and testing centres. In the global market,
Sysmex ranks in the top 10 in diagnostics. In haematology, it holds
the top share of the global market.

Overseas business development has been a focus for Sysmex since it
was founded. It operates R&D, production, sales and customer support
facilities around the world to ensure products and services are
delivered that meet the needs of the customer in each region.
Principal clinical areas of activity are: Haematology, Haemostasis,
Immunochemistry, Urinalysis, Clinical Chemistry and Life Science. For
more information please visit http://www.sysmex-lifescience.com

Editorial contact:
Terry Nicklin KeynotePR Ltd
Tel: +44 (0)7923 540695
E-mail: terry@keynotepr.com

Company contact:

Dr Eric Mayes, CEO Endomagnetics Ltd
Tel: +44 (0)1223 652540
E-mail: emayes@endomagnetics.com

or

Sysmex Europe GmbH
Ines Lühmann, Pressekontakt
luehmann.ines@sysmex-europe.com
Bornbarch 1, 22848 Norderstedt, Deutschland
Tel.: +49 (40) 527 26 0
Fax: +49 (40) 527 26 10 0
http://www.sysmex-europe.com